FDA Approves Autus: First Heart Valve Designed to Grow With the Child — and First Polymeric-Leaflet Valve Approved in the U.S.

FDA Approves Autus: First Heart Valve Designed to Grow With the Child — and First Polymeric-Leaflet Valve Approved in the U.S.

October 1, 2026. The FDA approved the Autus Size-Adjustable Valve (Edwards Lifesciences; developed by Autus Valve Technologies), a surgically implanted pulmonary valve for pediatric patients with congenital pulmonary valve disease. Per the FDA press announcement, it is "the first heart valve designed to be expanded after surgery to keep pace with a child's growth, and the first valve approved in the U.S. to use polymeric material rather than animal-derived tissue¹ for its inner flaps (called leaflets)."

The valve implants as small as ~13 mm in diameter (toddler/preschool-sized) and can later be widened with a balloon catheter up to 22 mm — comparable to an adult pulmonary valve — potentially sparing children with congenital heart defects the repeated open-heart surgeries that traditional tissue valves require as they grow. Michelle Tarver, MD, PhD, director of FDA's Center for Devices and Radiological Health: "For children born with congenital heart disease, valve replacement timing has always been a difficult decision — wait too long and you risk harm to the child, but intervene too early and they may need multiple open-heart surgeries as they grow. The Autus Size-Adjustable Valve gives doctors the option of far fewer trips to the operating room, which may result in better quality of life for these children and their families."

Evidence base: a clinical study of 62 pediatric patients across 12 U.S. sites. At six-month follow-up, the first 60 patients demonstrated acceptable hemodynamic performance with no more than mild leakage; there were no deaths, no blood clots requiring additional treatment, and no strokes. Three patients experienced valve-frame fractures and two had reduced movement of one leaflet — all without symptoms. Two patients whose valves began deteriorating as they outgrew them were successfully balloon-expanded without invasive surgery, though the FDA notes this experience is limited and longer-term studies are ongoing.

Why it's a first on three axes: the first FDA approval of polymeric leaflet material for any valve indication (traditional animal-tissue valves harden and break down faster in children); the first pediatric approval to come out of the agency's Total Product Life Cycle Advisory Program (TAP)²; and it was approved through the premarket approval (PMA) pathway, FDA's most stringent device pathway, after prior Breakthrough Device designation. Acting FDA Commissioner Kyle Diamantas called the approval "a historic turning point." Context: pulmonary valve atresia and stenosis together affect about 4,200 U.S. babies per year (CDC).